Beam Therapeutics Inc.’s BEAM share price has surged by 5.12%, which has investors questioning if this is right time to sell.

Authorities hope to establish a high-end oncological care system soon and that the Bathinda-based institute will be the first public-sector institute in the country to offer proton beam therapy.

The old Gauhati Medical College Hospital (GMCH) is set to be demolished to make way for a state-of-the-art 3,000-bed medical facility.

Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector ...

The equipment for the treatment is tipped to be ₹500 cr and has fewer side effects than traditional radiation therapy ...

Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

Methodist University and Cape Fear Valley Health celebrated the placement of the final beam on their new medical school ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.